ClinicalTrials.gg
RecruitingNCT06299800TCPT2023Updated Oct 29, 2026

Phenotyping Patients With Type 2 Diabetes Mellitus and Cancer

An observational study in Diabetes Mellitus, Type 2 and Cancer, sponsored by Azienda Ospedaliero Universitaria Maggiore della Carita. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Azienda Ospedaliero Universitaria Maggiore della Carita · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Oct 29, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
779
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy — 45 open to participants now, 61 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Italy.

Planned enrollment
46th of 99
779 · median 500
Started
2024
with 21 others
Observational
99 of 421
19 open now
Primary completion
2025-02
later than 6 of 60 live
Registered
368th of 421
by date

Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, this one is the 46th largest by planned enrollment of the 99 observational ones that give a count, is one of 22 that started in 2024, is one of 99 observational ones, reaches primary completion later than 6 of the 60 other live ones, and was the 368th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

45 of the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, or all of them as a file.
02

Study summary

Recent research has highlighted the significant relationship between type 2 diabetes mellitus and cancer, both prevalent and impactful on global health. The intrinsic correlation arises from shared metabolic processes, particularly a systemic and chronic inflammatory state driven by factors like obesity, dyslipidemia, and hyperglycemia. This leads to the creation of a self-sustaining microenvironment known as meta-inflammation, promoting cancer development through DNA damage, oxidative stress, and the influence of hormones like leptin. The hyperglycemic environment in diabetes contributes to cancer development, supporting the Warburg effect and insulin-related mechanisms. This study aims to identify risk factors associated with diabetes that impact tumor development and progression, crucial for guiding effective preventive strategies in clinical practice.

Primary objective of the study:

- identify the risk factors affecting the occurrence of cancer in the population affected by type 2 diabetes mellitus;

Secondary objectives of the study:

  • description of the demographic, clinical and first-line therapy characteristics of patients diagnosed with type 2 diabetes mellitus;
  • assess risk factors for recurrence, presence of a second tumour not related to the first and the presence of both events in patients who have had a tumor within 10 years of diagnosis of diabetes;
  • assess the relationship between the characteristics of patients and the time to the onset of cancer.
Read the detailed description

Study design This study is a monocentric retrospective cohort study based on the data available in the Smart Digital Clinic (Meteda Srl) electronic medical record.

Participating centre Surgery of Endocrinology and Diabetology of the SCDU of Novara, University of Eastern Piedmont. Responsible: Prof.ssa Flavia Prodam

Subjects Will be included in the study all patients visited at the Endocrinology and Diabetology surgery of the AOU Major of the Charity of Novara for an initial diagnosis of diabetes mellitus type 2 between 1990 and 2010.

Inclusion criteria

  • Legal age
  • Diagnosis of type 2 diabetes mellitus Exclusion criteria
  • Diagnosis of cancer before diagnosis of type 2 diabetes
  • Diagnosis of diabetes secondary to other diseases
  • Diagnosis of diabetes secondary to other drugs
  • Diagnosis of diabetes following surgery

Duration of study: 24 months

Follow-up and events of interest Patients included in the study will be followed from the date of diagnosis of type 2 diabetes mellitus until the date of the last available examination.

During the follow-up, for all patients included, the year of onset of the first cancer after the diagnosis of diabetes and the type of tumor will be detected. From this information it will be possible to calculate the time between the diagnosis of diabetes and the onset of cancer (measured in years).

For patients who have developed a first tumor will also be detected:

  1. Recurrence of cancer (year of onset of recurrence)
  2. Diagnosis of second tumour not related to primary tumour (year of onset, type of tumour) The diagnosis of cancer will be identified through the extraction system from the electronic medical record Smart Digital Clinic (Meteda Srl), using key words relevant to the area of cancer, identified in the section of the medical history. The key words will be: metastasis, adenocarcinoma, carcinoma, neoplasm, secondary/s, sarcoma, tumor, adenoma, lymphoma, leukemia, glioma, glioblastoma, ependymoma, basalioma, epithelium, melanoma, mesothelioma, cordoma, anaplastic, differentiated, undifferentiated, meningioma, multiple myeloma, small cell carcinoma, timoma, craniopharyngioma, neuroendocrine, LH, LNH, K, GIST, HCC and NET.

Data collection

For each patient, the following variables will be extracted from the Smart Digital Clinic electronic medical record for all visits available after diagnosis, where possible:

  • Gender and age;
  • Smoking habits and alcohol consumption (units per day);
  • Weight and body mass index (BMI) at first (T0) and last visit (T1);
  • Given by the diagnosis of type 2 diabetes mellitus;
  • Treatment of type 2 diabetes mellitus at T0 and T1;
  • Levels of glycated hemoglobin (hba1c) at T0 and T1, mean hba1c and mean fasting blood sugar;
  • Creatinine clearance at T0 and T1;
  • Liver enzymes at T0 and T1: alanine aminotransferase (ALT) and aspartate aminotransferase (AST);
  • T0 and T1 lipid profile: low density lipoproteins (LDL-c) and triglycerides (TG);
  • Complications of type 2 diabetes mellitus;
  • Treatment of cancer;
  • Family history of cancer; The diagnosis of type 2 diabetes mellitus is confirmed at diabetological centres or, in some cases, by general practitioners who refer patients to specialised diabetological centres. The accuracy of the diagnosis will be confirmed by crossing the Piedmont Diabetic Registry (PDR) and involving a second person to ensure a precise assessment.

BMI categories will be divided into underweight (BMI \<18.5 Kg/m2), normal weight (BMI 18.5 - 25 Kg/m2), and overweight (BMI >25 Kg/m2).

With regard to the treatment of type 2 diabetes mellitus, participants will be categorised and grouped for statistical purposes in the following classes:

  • Dietary therapy;
  • Metformin/Acarbosio;
  • Sulfanilurea;
  • Metformin + GLP1/ DDPIV inhibitors (DDPIVi) or only GLP1 or only DDPIVi;
  • Metformin + SGLT2i inhibitors (SGLT2i) or only SGLT2i;
  • Basal insulin + GLP1/DDPIVi +/- Metformin;
  • Basal insulin +/- Metformin +/- SGLT2i;
  • Insulin basal bolus;
  • Basal insulin bolus +/- Metformin +/- SGLT2i. In addition, complications of metabolic pathology will be extracted from the dedicated section of the program, where are systematically recorded and organized, and the diagnosis of which is conducted in accordance with the appropriate guidelines. These complications will be divided into the following categories: vasculopathy, neuropathy, hypertension, heart disease, kidney failure and retinopathy.

Finally, as regards cancer pathology, a categorization of treatment will be carried out in three classes: chemotherapy, surgery and radiation therapy.

In addition, the types of cancer will be divided in order to ensure greater homogeneity between groups, including the nervous system, head and neck, thorax, gastrointestinal, gynecological, urinary tract, male genital system, skin, blood, breast, soft tissues, endocrine glands and neuroendocrine tumors. This information will be collected at the diabetes diagnosis visit and at the last visit before the onset of cancer for the subjects experiencing the event and at the last available visit for the remaining subjects.

EXPECTED RESULTS Through this research, the investigators aim to obtain new information on the study population in order to better understand the possible correlation between the two pathologies. This will allow us to identify the risk factors associated with metabolic pathology that can affect the development time of cancer pathologies, as well as to identify those that could contribute to carcinogenesis itself.

This knowledge will allow us to define the role of hyperglycemia, obesity and other factors or behaviors at risk in the field of cancer in order to act with appropriate prevention strategies, thus considering the tumor pathology as one of the possible complications of type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Cancer

Keywords

  • cancer
  • diabetes mellitus type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

779 patients with diabetes mellitus type 2 and with at least 18 years old.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Legal age
  • Diagnosis of type 2 diabetes mellitus

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of cancer before diagnosis of type 2 diabetes
  • Diagnosis of diabetes secondary to other diseases
  • Diagnosis of diabetes secondary to other drugs
  • Diagnosis of diabetes following surgery
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
779 participants (estimated)
Patient registry
No

Groups and cohorts

  • Diabetes mellitus type 2 and cancer

    779 patients with cancer and diagnosis of type 2 diabetes mellitus diagnosed between 1990 and 2010

    Other: phenotyping of patients followed at a third-level diabetes centre with cancer

Interventions

  • Otherphenotyping of patients followed at a third-level diabetes centre with cancer

    Collection of the following data for each patient enrolled, where possible: * Gender and age; * Smoking habits and alcohol consumption (units per day); * Weight and body mass index (BMI) at first (T0) and last visit (T1); * Given by the diagnosis of type 2 diabetes mellitus; * Treatment of type 2 diabetes at T0 and T1; * Levels of glycated hemoglobin (hba1c) at T0 and T1, mean hba1c and mean fasting blood sugar; * Creatinine clearance at T0 and T1; * Liver enzymes at T0 and T1: alanine aminotransferase (ALT) and aspartate aminotransferase (AST); * T0 and T1 lipid profile: low density lipoproteins (LDL-c) and triglycerides (TG); * Complications of type 2 diabetes; * Treatment of cancer; * Family history of cancer.

06

What researchers measure

Primary outcomes

  1. Smoking assessment at first visit

    identify the risk factors affecting the occurrence of cancer in the population affected by type 2 diabetes mellitus: During the first examination, the history of each patient was investigated, evaluating whether they were smokers, non-smokers or ex smokers

    Time frame: Assessment of data at time 0 (first clinical visit)

  2. Alcool consumption at first visit

    identify the risk factors influencing the onset of cancer in the population affected by type 2 diabetes mellitus: During the first examination, the history of each patient was studied, assessing whether I consume alcohol and in what amount. \<1 alcohol unit or greater than 2 alcohol units were used as cutoffs to subdivide the patients considered.

    Time frame: Assessment of data at time 0 (first clinical visit)

  3. BMI assessment at first visit

    identify the risk factors influencing the onset of cancer in the population affected by type 2 diabetes mellitus: During the first examination, the history of each patient was studied, measuring weight and height to calculate the BMI of each patient. The ranges considered are: underweight \<18.5, normal weight 18.5-25 and overweight \>25.

    Time frame: Assessment of data at time 0 (first clinical visit)

  4. Glycated assessment at first visit

    identify the risk factors influencing the onset of cancer in the population affected by type 2 diabetes mellitus: During the first examination, the history of each patient was studied, measuring the glycate of each patient. The considered cutoff is \< or equal to 8%, where 8% is the limit for glycemic decompensation.

    Time frame: Assessment of data at time 0 (first clinical visit)

Secondary outcomes

  1. First-line therapy characteristics assessment at first visit

    Detection of drug therapy given at the first visit considering the medical record. The therapies considered were: Dietotherapy, Metformin/Acarbosio, Sulfanilurea, Metformin + GLP1/DDPIVi or GLP1 alone or DDDPIVi alone, Metformin + SGLT2i or SGLT2i alone, Basal insulin + GLP1/DPIVi +/- Metformin, Basal Insulin +/- Metformin + SGT2i, Insulin Basal Bolus, Insulin Basal Bolus +/- Metformin +/- SGLT2i

    Time frame: Assessment of data at time 0 (first clinical visit)

  2. Primary outcomes and recurrence or presence of a secondary tumor

    Considering the risk factors measured as primary findings, it was intended to observe a possible association with those who had recurrence or with the development of a secondary tumour unrelated to the first, within 10 years of the diagnosis of diabetes. Detected during first clinical visit signed in the medical record

    Time frame: Assessment of data at time 0 (first clinical visit)

  3. Relationship between patients characteristics and the time onset of cancer considering anthropometric and biochemical data

    Assess the relationship between the characteristics of patients and the time to the onset of cancer using medical record

    Time frame: Assessment of data at time 0 (first clinical visit)

  4. Tumour characterization in the considered population, detected at the first clinical visit

    Characterization of tumors: tumors of the nervous system, head neck, thoracic, gastrointestinal, gynecological, urological, male genital, cutaneous, haematological, breast, soft tissue, endocrine glands, neuroendocrine and bone tumors. Detected during first clinical visit considering the medical record.

    Time frame: Assessment of data at time 0 (first clinical visit)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013 Jan 1;9(1):25-53. PubMed 22974359 ↗
  • Rojas A, Schneider I, Lindner C, Gonzalez I, Morales MA. Association between diabetes and cancer. Current mechanistic insights into the association and future challenges. Mol Cell Biochem. 2023 Aug;478(8):1743-1758. doi: 10.1007/s11010-022-04630-x. Epub 2022 Dec 24. PubMed 36565361 ↗
  • Cignarelli A, Genchi VA, Caruso I, Natalicchio A, Perrini S, Laviola L, Giorgino F. Diabetes and cancer: Pathophysiological fundamentals of a 'dangerous affair'. Diabetes Res Clin Pract. 2018 Sep;143:378-388. doi: 10.1016/j.diabres.2018.04.002. Epub 2018 Apr 19. PubMed 29679627 ↗
  • Francisco V, Pino J, Campos-Cabaleiro V, Ruiz-Fernandez C, Mera A, Gonzalez-Gay MA, Gomez R, Gualillo O. Obesity, Fat Mass and Immune System: Role for Leptin. Front Physiol. 2018 Jun 1;9:640. doi: 10.3389/fphys.2018.00640. eCollection 2018. PubMed 29910742 ↗
  • Chiefari E, Mirabelli M, La Vignera S, Tanyolac S, Foti DP, Aversa A, Brunetti A. Insulin Resistance and Cancer: In Search for a Causal Link. Int J Mol Sci. 2021 Oct 15;22(20):11137. doi: 10.3390/ijms222011137. PubMed 34681797 ↗
  • Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):407-20. doi: 10.1016/j.cytogfr.2005.01.010. PubMed 15886048 ↗
  • Mao Z, Zhang W. Role of mTOR in Glucose and Lipid Metabolism. Int J Mol Sci. 2018 Jul 13;19(7):2043. doi: 10.3390/ijms19072043. PubMed 30011848 ↗
  • Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017 Mar 9;168(6):960-976. doi: 10.1016/j.cell.2017.02.004. PubMed 28283069 ↗
  • Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012 Apr 13;149(2):274-93. doi: 10.1016/j.cell.2012.03.017. PubMed 22500797 ↗
  • Shlomai G, Neel B, LeRoith D, Gallagher EJ. Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy. J Clin Oncol. 2016 Dec 10;34(35):4261-4269. doi: 10.1200/JCO.2016.67.4044. Epub 2016 Nov 7. PubMed 27903154 ↗
  • Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271-281. doi: 10.1016/j.diabres.2018.02.023. Epub 2018 Feb 26. PubMed 29496507 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2024 to primary completion in Feb 2025, 12 months.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2025 → Feb 2027, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2024
First posted
Mar 8, 2024
StartActual
Feb 4, 2024
Primary completionActual
Feb 4, 2025
CompletionEst.
Feb 4, 2027was Feb 2025
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Feb 4, 2025→Feb 4, 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Study completion Feb 4, 2025→Feb 4, 2027
    + 4 other changes: verification date, description, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06299800
Lead sponsor
Azienda Ospedaliero Universitaria Maggiore della Carita
Responsible party
Flavia Prodam (Professor, Azienda Ospedaliero Universitaria Maggiore della Carita) — Principal investigator
First posted
Mar 8, 2024
Start date
Feb 4, 2024
Primary completion
Feb 4, 2025
Completion
Feb 4, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Flavia Prodam, MD PhD
Contact
flavia.prodam@med.uniupo.it
+39 0321 660 693
Flavia Prodam, MD PhD
principal investigator · AOU Maggiore della Carità di Novara

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion